NASD · Healthcare · Biotechnology · USA
Rigel Pharmaceuticals is a small cap company (market value between $300 million and $2 billion) in the Biotechnology industry.
Rigel Pharmaceuticals is a biotechnology company developing therapies for hematologic disorders and cancer. It commercializes TAVALISSE for chronic immune thrombocytopenia, REZLIDHIA for relapsed or refractory acute myeloid leukemia with IDH1 mutations, and GAVRETO for RET fusion-positive cancers. The company also operates development programs in myelodysplastic syndrome and collaborates with partners on oncology candidates.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the Rigel Pharmaceuticals stock.
No reliable verdict: intrinsic value $270.83 per share, market price $51.31 (as of 2026-10-30).
Discounting its cash flows would put the shares at $270.83: 5 times the price of $51.31. A gap that size says more about a model than about the market. It usually means heavy debt, where a small error in the value of the business becomes a large one in the value of the shares, or a business our method does not describe. We do not publish a verdict on this one.
Leak Score: 82/100 on 12 of 12 signals (Strong Leak).
17 more funds hold it; the full list is part of the paid plan.
We do not publish a verdict on RIGL. Discounting its cash flows would put the shares at $270.83: 5 times the price of $51.31. A gap that size says more about a model than about the market. It usually means heavy debt, where a small error in the value of the business becomes a large one in the value of the shares, or a business our method does not describe. We do not publish a verdict on this one.
We do not publish one (as of the 2026-10-30 close). Discounting its cash flows would put the shares at $270.83: 5 times the price of $51.31. A gap that size says more about a model than about the market. It usually means heavy debt, where a small error in the value of the business becomes a large one in the value of the shares, or a business our method does not describe. We do not publish a verdict on this one.
82 out of 100, which we rate "Strong Leak", on 12 of 12 value investing signals.